Acelyrin Stock

acelyrin.comHealthcareFounded: 2020Funding to Date: $558MM

Acelyrin is a biopharma company that invests in, develops and commercializes life-changing innovative therapeutics and transformative medicines. Acelyrin partners with big pharmaceutical companies, early-stage startups, and academia with a blend of scientific, medical, operational, and company-building experience to bring its treatments and therapeutics to the public, and transform patient's lives through healing and wellbeing.

Register for Details

For more details on financing and valuation for Acelyrin, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Acelyrin.

Register Today

Acelyrin investors also invested in these private companies

Marshall Wace
Westlake Village BioPartners
OrbiMed Healthcare Fund Management
Samsara Biocapital
Tybourne Capital Management


Management Team

Shao-Lee Lin, MD, PhD
Chief Executive Officer
Robert F. Carey
Paul Peloso
Chief Medical Officer
Melanie Gloria
Chief Operating Officer
Gil Labrucherie
Chief Financial Officer
Ron Oyston
Senior Vice President, Human Resources
Marc Kubasak
Vice President, Program Lead & Regulatory Affairs
Brian Wiens
Vice President, Biostatistics and Data Sciences
Terry Bevirt
Vice President, Alliance Management, Clinical & Corporate Quality
Katherine To
Vice President - Clinical Operations
Suzy Buckhalter
Senior Director, Finance & Accounting
Tyler Marciniak
Head of Investor Relations and Communications
Shawn Eisnberg
Vice President, Technical Operations

Board Members

Sean Harper
Kin Insurance
Alan Colowick
Sofinnova Investments
Beth Seidenberg
Westlake Village BioPartners
Dan Becker
Access Biotechnology
Richard Gaster
venBio Partners

Other companies like Acelyrin in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


Drugmaker Acelyrin has raised $300 million in new venture capital to run late-stage clinical trials of a drug that could treat certain forms of arthritis and other conditions and compete with top-selling medications.
Updated on: Jun 4, 2023